|
Aesop Technology tackles a different challenge: information overload. Founded as a research project at Taipei Medical University (TMU) in 2011, Aesop began by detecting prescription errors in Taiwan’s vast NHI database. Today, it has evolved into a comprehensive clinical-decision platform that uses AI to guide doctors through complex treatment pathways in real time. Aesop Technology cofounder and Chief Product Officer Jeremiah Scholl argues that some of the most transformative uses of AI come from decision support. “Our AI doesn’t tell doctors what to do — it helps them find the information they are looking for to make decisions much faster,” he says. Embedded directly into hospital electronic records, Aesop’s software, named 𝗠𝗲𝗱𝗶𝗴𝗮𝘁𝗼𝗿, automatically loads the latest U.S. National Comprehensive Cancer Network (NCCN) cancer-treatment guidelines, cross-checks them with patient data, and provides physicians with the most recent published evidence that is relevant for their patient. Of the products Aesop offers, Medigator continuously scans journals and clinical-trial databases, updating recommendations within hours of new findings — a process Scholl describes as “bringing the latest data quietly into the doctor’s workflow.” The platform was made possible through the national data exchange already established in Taiwan, which has allowed physicians to share patient data securely across hospitals. The foundational research projects at TMU obtained access to this data to develop the AI models it uses, showing how Taiwan’s healthcare infrastructure is shaping the island into an AI-enabled healthcare powerhouse. At a broader level, Aesop’s analytics evaluate how well hospitals adhere to international standards and where real-world results diverge, giving tumor boards and research partners a clearer picture of where care can improve. By connecting guidelines with real outcomes, Scholl says, Taiwan’s hospitals can turn overwhelming data into practical insight — “making accuracy routine, not exceptional.” *This is an excerpt from the article.
Digging for data Any AI system needs to learn from data – the more the better. Taiwan has a trove of data to feed on thanks to its National Health Insurance (NHI)system, which was launched in 1995 and covers more than 99% of the population. In recent years, the government has allowed access to this extensive data for research and development. One startup to take advantage of this opportunity is AESOP Technology, which has offices in Taipei, Berkeley, California, and Cambridge, Massachusetts. AESOP is trying to reduce a major risk to patients’ health globally: medical errors, specifically prescription errors. In Taiwan, they analyzed NHI data and found at least 3 million incorrect prescriptions each year, from incorrectly filled out forms to prescribing the wrong drugs or dosages. “Everyone thinks hospitals are high-tech, but in hospitals, the staff records patients’ status on white boards,” said Jim Long, CEO of AESOP. “Doctors spell drug names wrong – even common drug names that sound like and look like other drug names.” Traditionally, the industry has used rule-based reminders, which look at one or two variables – such as whether two specific drugs are prescribed together. A lot of noisy alerts are generated that physicians often ignore or turn off. AESOP is unique in that it considers many more variables – from four to more than 20 – when deciding whether to send an alert. These include a patient’s age, gender, the hospital department involved, and the diagnosis. Its system uses machine-learning to flag outliers, signaling a potential mistake. Long and his business partner founded AESOP – a spin-off startup from Taipei Medical University – last year but had first started trying to address the problem of prescription errors 20 years ago. Two developments over the past five years have been instrumental in making this technology possible, says Long. The first is greater computational power. Given that there are 60,000 possible clinical diagnoses adjusted for patients’ gender, ages, medication, and so on, just five years ago Long and his team estimated that “to finish a round of machine learning would take 150 years.” The second key change was the opening of Taiwan’s NHI Administration’s database to biotechnology and healthcare firms through academic research cooperation. Since 2016, such access to anonymized healthcare data for Taiwan’s population going back to 1995 has been available upon application. This is much more than the maximum 50 million prescriptions AESOP is allowed to access and purchase from public sources in the U.S.,Long said. In a bid to protect privacy, researchers and companies are not allowed to take any notes inside the data center in Nangang. They can only use the center’s computers and then provide the result of their searches to the staff, who then check it and send it to them. AESOP’s MedGuard system has been in use in three hospitals in Taiwan since 2017. This year, the company has signed up more hospitals in Taiwan, and physicians at Harvard Medical School’s Brigham and Women’s Hospital are also giving the system a trial. “Our target will still be the U.S.,” says Long. The U.S. is a bigger market than Taiwan and uses the same drug coding system and language when prescribing, he says. One prescription error it caught in Taiwan involved a 9-year-old girl with lower back pain. The physician had meant to prescribe Solaxin, a muscle relaxant. Instead, he chose Solian, an antipsychotic used to treat schizophrenia. The drug should not be prescribed to children and the dosage far exceeded the maximum recommended amount. AESOP’s MedGuard system flagged the error when it recognized that the drug wasn’t being prescribed as it had been in the past. Reference: Taiwan Business TOPICS |
All
|